Stock market today: Dow, S&P 500, Nasdaq snap 3-day losing streak as bonds rally, Moderna skyrockets

Moderna and Merck's phase 3 melanoma vaccine trial showed reduced risk of tumor recurrence or metastasis. The personalized mRNA therapy, combined with Keytruda, met primary endpoints. Detailed data will be presented later. The companies plan regulatory discussions. The vaccine is not yet commercially available, and overall survival data is pending. The trial marks the first successful phase 3 for personalized mRNA cancer therapy.

Moderna (MRNA) stock surged after positive cancer vaccine results. Analysts had a consensus 'Hold' rating with a $53 price target. The stock moved above key moving averages, with an RSI near 90, indicating strong buying pressure.

Moderna and Merck's Phase 3 trial for their personalized mRNA cancer vaccine, intismeran autogene, met primary and key secondary endpoints in high-risk melanoma patients. The treatment, combined with Merck's Keytruda, could be available as early as next year, pending regulatory feedback. The companies are also studying the therapy in other cancers. Experts suggest the success may accelerate personalized medicine and AI use in healthcare, potentially changing cancer treatment economics and access

Moderna and Merck announced that a personalized mRNA vaccine, intismeran, combined with Keytruda, reduced melanoma recurrence in a late-stage trial. The vaccine is tailored to each patient's tumor genetics. Full data will be presented at a medical meeting and shared with regulators. The companies expect 112,000 new U.S. melanoma cases and 8,500 deaths this year, according to their announcement.

Moderna's shares have surged 402% this year, driven by FDA approval of its flu vaccine, mFLUSIVA, and positive phase 3 results for its cancer vaccine, intismeran autogene. The company's mRNA platform shows promise beyond COVID-19, with a deep pipeline in infectious diseases and oncology. Despite financial challenges, investors see long-term potential in its pipeline.

Moderna's stock surged 177% after announcing positive clinical trial results for an experimental cancer vaccine developed with Merck. The vaccine, using mRNA technology, extended recurrence time in melanoma patients. Moderna's stock later fell 24% to $133.32. Analysts see cancer as a significant growth opportunity for Moderna, despite past challenges and political headwinds.